**Claims**

1. Use of a pharmaceutical composition which comprises (i) adipose tissue-derived cell secretions, or (ii) an adipose tissue-derived cell suspension, or (iii) a combination of (i) and (ii), in the manufacture of a medicament for alleviating pain in a mammalian subject.

2. The use according to claim 1, wherein the pharmaceutical composition is to be administered to said subject by intra-articular injection or by intramuscular injection or by subcutaneous injection or by topical administration.

3. The use according to claim 1, wherein the pain is back pain, or is pain associated with a burn injury, an inflammatory disorder, a ligament injury, a tendon injury, or the sciatic nerve, or is neuropathic pain.

4. The use according to claim 3, wherein the neuropathic pain is facial pain, pain of the teeth, jaw, gum or of a limb.

5. The use according to claim 1, wherein the adipose tissue-derived cell suspension (i) comprises adipocytes or (ii) is substantially free of adipocytes.

6. The use according to claim 1, wherein the subject is to be selected from the group consisting of (i) a human, (ii) poultry, (iii) an equine animal, (iv) a feline animal, (v) a canine animal, (vi) a bovine animal, and (vii) a porcine animal.

7. The use according to claim 1, wherein the adipose tissue-derived cell secretions or the adipose tissue-derived cell suspension is (i) derived from adipose tissue allogeneic to the recipient subject or animal, or (ii) derived from the intended recipient subject or animal, or (iii) derived from adipose tissue xenogeneic to the recipient subject or animal.

8. The use according to claim 1, wherein the adipose tissue-derived cell secretions is a preparation concentrated by between 2-fold and 20-fold.

9. The use according to claim 1, wherein said adipose tissue-derived cell secretions comprises concentrated media from culture of an adipose tissue-derived cell suspension,

optionally wherein said adipose tissue-derived cell suspension (i) comprises adipocytes and adipose tissue-derived mesenchymal stem cells or (ii) is substantially free of adipocytes,

optionally wherein said media from culture of an adipose tissue-derived cell suspension is concentrated between 2-fold and 20-fold.

10. The use according to claim 1, wherein the use further comprises (i) thawing frozen adipose tissue-derived cell secretions, or (ii) thawing frozen adipose tissue-derived cell suspension, or (iii) thawing a froz[illegible] 70a [illegible]ination of adipose tissue-derived cell secretions and an adipose tissue-derived cell suspension, or (iv) thawing a frozen pharmaceutical composition of any of (i), (ii) or (iii), prior to administration to the recipient subject or animal.

11. The use according to claim 10, wherein the frozen secretions, cell suspension, combination thereof, or pharmaceutical composition thereof, is to be administered to the recipient subject or animal within two hours of thawing.

12. A kit comprising (a) a pharmaceutical composition selected from the group consisting of (i) a composition comprising adipose tissue-derived secretions, (ii) a composition comprising an adipose tissue-derived cell suspension, and (iii) a combination of (i) and (ii); and (b) instructions for use of said kit in alleviating pain in a mammalian subject.

13. The kit according to claim 12, wherein the pain is back pain, or is pain associated with a burn injury, an inflammatory disorder, a ligament injury, a tendon injury, or the sciatic nerve, or is neuropathic pain, optionally wherein the neuropathic pain is facial pain, pain of the teeth, jaw, gum or of a limb.

14. The kit according to claim 12, wherein the adipose tissue-derived cell suspension (i) comprises adipocytes, or (ii) is substantially free of adipocytes.

15. The kit according to claim 12, wherein the kit comprises one or more frozen compositions and optionally further comprises instructions for administration of said composition within 2 hours of thawing said frozen composition.

16. The kit according to claim 12, wherein the adipose tissue-derived cell secretions or the adipose tissue-derived cell suspension is (i) derived from adipose tissue allogeneic to the recipient subject or animal, or (ii) derived from the intended recipient subject or animal, or (iii) derived from adipose tissue xenogeneic to the recipient subject or animal.

17. The kit according to claim 12, wherein the adipose tissue-derived cell secretions is a preparation concentrated by between 2-fold and 20-fold.

18. The kit according to claim 12, wherein said adipose tissue-derived cell secretions comprises concentrated media from culture of an adipose tissue-derived cell suspension,

optionally wherein said adipose tissue-derived cell suspension (i) comprises adipocytes and adipose tissue-derived mesenchymal stem cells or (ii) is substantially free of adipocytes,

optionally wherein said media from culture of an adipose tissue-derived cell suspension is concentrated between 2-fold and 20-fold.

**Claims**

1. Use of adipose tissue-derived cell secretions for the manufacture of a medicament for the treatment of an inflammatory condition in a subject, wherein said secretions comprise media from culture of a multiply-passaged adipose tissue-derived cell line, wherein in said manufacture said secretions are mixed with multiply-passaged cells from an adipose tissue-derived cell suspension, said mixture is stored frozen under appropriate conditions, and wherein said mix is suitable for administration as a medicament to a subject in need thereof within two hours of retrieval from frozen storage.

2. The use according to claim 1, wherein the inflammatory condition is selected from the group consisting of osteoarthritis, stifle disease, wobblers, a tendon injury, a ligament injury, atopic dermatitis, rheumatoid arthritis, back pain, and multiple sclerosis.

3. The use according to claim 1 or 2, wherein the inflammatory condition is osteoarthritis.

4. The use according to any one of claims 1 to 3, wherein the medicament is suitable for administration to said subject by intra-articular injection.

5. The use according to any one of claims 1 to 4, wherein the subject is a human.

6. The use according to any one of claims 1 to 5, wherein said multiply-passaged cells are (i) of a cell line that has been passaged more than five times, or (ii) of a cell line that has been passaged more than ten times.

7. The use according to any one of claims 1 to 6, wherein said multiply-passaged cells are of a cell line that has been frozen multiple times.

8. The use according to claim 1, wherein the multiply-passaged cells are mesenchymal stem cells.

9. The use according to claim 1, wherein the adipose tissue-derived cell secretions comprise clarified media from culture of adipose tissue-derived cells.

10. The use according to claim 1, wherein the adipose tissue-derived cell secretions is a concentrated preparation of media from culture of adipose tissue-derived cells.

11. The use according to claim 1, wherein the adipose tissue-derived cell secretions is a preparation concentrated between 2-fold and 20-fold.

12. The use according to claim 1, wherein, prior to said storing, the secretions and cells mix is held at room temperature for up to one hour.

13. The use according to claim 1, wherein in said manufacture said mix of adipose tissue-derived secretions and cells does not comprise fresh medium.

14. The use according to claim 1, wherein the adipose tissue-derived cell secretions and the multiply passaged cells are derived from adipose tissue allogeneic to the recipient subject or animal.